Lung Cancer
Volume 69, Issue 1 , Pages 94-98 , July 2010

Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer

  • Su-Hee Cho

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • These authors contributed equally to this work.
    • ,
  • Se-Il Go

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • These authors contributed equally to this work.
    • ,
  • Gyeong-Won Lee

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine Gyeongsang National University, 660-702 Jinju, Republic of Korea. Tel.: +82 55 750 8066; fax: +82 55 758 9122.
    • ,
  • Jung Hun Kang

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • ,
  • Hoon-Gu Kim

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • ,
  • Seok Hyun Kim

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • ,
  • Yu Ji Cho

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • ,
  • Yi Yeong Jeong

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • ,
  • Ho-Cheol Kim

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • ,
  • Jong Duk Lee

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea
    • ,
  • Young Sil Hwang

      Affiliations

    • Department of Internal Medicine, School of medicine Gyeongsang National University, Jinju, Republic of Korea
    • Gyeongsang Institute of Health Science, Jinju, Republic of Korea
    • Gyeongnam Regional Cancer Center, Jinju, Republic of Korea

Received 30 June 2009 ,Revised 3 September 2009 ,Accepted 8 September 2009.

References 

  1. Bae JM, Won YJ, Jung KW, Park JG. Annual Report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res Treat. 2002;34:77–83
  2. Cappuzzo F, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer. 2005;93:29–34
  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  4. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37:S4–S66
  5. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2000;2:CD002139
  6. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087–1100
  7. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–353
  8. Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, van Meerbeek J, et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 1994;70:384–387
  9. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12:1232–1237
  10. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:1238–1244
  11. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995;13:645–651
  12. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000;18:131–135
  13. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354–2362
  14. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  15. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996;14:1649–1655
  16. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164–2168
  17. Briasoulis E, Karavasilis V, Anastasopoulos D, Tzamakou E, Fountzilas G, Rammou D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol. 1999;10:701–706
  18. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol. 1999;26:28–31
  19. Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ, Chen YM, et al. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol. 2005;35:700–706
  20. Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, et al. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer. 2007;109:732–740
  21. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23:8389–8395
  22. Camps C, Massuti B, Jiménez A, Maestu I, Gómez RG, Isla D, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006;17:467–472
  23. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16:90–96
  24. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006;129:1031–1038
  25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  27. Goh BC, Lehnert M, Lim HL, Ng AW, Chan CC, Kong HL, et al. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncol. 2000;39:225–229
  28. Miyata M, Yasuda K, Burioka N, Takane H, Suyama H, Shigeoka Y, et al. The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients. Cancer J. 2006;12:69–72
  29. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20:3683–3690
  30. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12:5786–5793
  31. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004;91:1996–2004
  32. Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:1377–1382
  33. Iwasaki Y, Ohsugi S, Natsuhara A, Tsubokura T, Harada H, Ueda M, et al. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemother Pharmacol. 2006;58:735–741
  34. Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, et al. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol. 2004;53:25–32
  35. Frasci G, D’Aiuto G, Thomas R, Comella P, Di Bonito M, Lapenta L, et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients. Oncology. 2005;68:391–397
  36. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19:1882–1887
  37. Oishi T, Kigawa J, Fujiwara K, Fujiwara M, Numa F, Aotani E, et al. A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol. 2003;90:421–424
  38. Mäenpää J, Leminen A. Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study. Cancer Chemother Pharmacol. 2009;64:297–300

PII: S0169-5002(09)00489-9

doi: 10.1016/j.lungcan.2009.09.005

Lung Cancer
Volume 69, Issue 1 , Pages 94-98 , July 2010

Article Tools

* Image Usage & Resolution